Plasma cathepsin L: A prognostic marker for pancreatic cancer

Table 2 Comparison of survival between groups in patients with carcinoma of pancreas (n = 127)

Parameters	No. of cases	Death n (%)	Median survival in months (95%CI)	P value1
Age(yr):
< 55	58	46 (80.0)	5 (3.1-6.8)	0.313
≥ 55	69	54 (78.2)	7 (4.9-9.0)
Sex:
Male	88	70 (80.4)	6 (4.9-7.0)	0.682
Female	39	30 (77.0)	5 (2.1-7.9)
Tumor mass (cm):
≥ 2	101	82 (81.0)	6 (4.5-7.4)	0.202
< 2	26	18 (72.0)	5 (2.1-7.8)
Vascular encasement:
No	65	46 (71.8)	6 (3.7-8.3)	0.003
Yes	62	53 (86.8)	4 (2.4-5.5)
Locally advanced:
No	39	28 (73.6)	8 (5.1-10.8)	0.008
Yes	88	72 (81.8)	5 (3.3-6.6)
Lymphatic invasion:
No	73	55 (76.3)	6 (4.5-7.5)	0.231
Yes	54	45 (85.0)	6 (4.0-8.0)
Metastasis:
No	74	55 (74.3)	9 (7.0-11.0)	0.001
Yes	53	45 (86.5)	3 (2.0-4.0)
Surgery:
No	102	81 (79.4)	6 (4.7-7.2)	0.349
Yes	25	20 (80.0)	6 (4.4-7.5)
Chemotherapy:
Yes	73	57 (79.0)	6 (4.2-7.7)	0.602
No	54	43 (79.6)	4 (1.1-6.8)
Stage:
I + II	48	35 (72.9)	9 (5.5-12.4)	0.004
III + IV	79	66 (83.5)	5 (3.3-6.6)
Cathepsin L:
Low ( ≤ 5 ng/mL)	54	38 (70.3)	9 (6.7-11.2)	0.004
High (> 5 ng/mL)	73	63 (86.3)	4 (2.5-5.4)

¹Log rank test.